BCRX (BioCryst Pharmaceuticals) Cyclically Adjusted FCF per Share: $-0.60 (As of Mar. 2026)


BCRX BioCryst Pharmaceuticals Inc BCRX
66 GF Score
Price $10.99
GF Value $12.59
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals Cyclically Adjusted FCF per Share?

BioCryst Pharmaceuticals BCRX +7.96% 66 Cyclically Adjusted FCF per Share is $-0.60 as of Mar. 2026. GuruFocus rates BCRX with a GF Score™ of 66/100 and a GF Value™ of $12.59 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BioCryst Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.257. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.60 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 8.30% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 1.80% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of BioCryst Pharmaceuticals was 8.30% per year. The lowest was -4.60% per year. And the median was -0.85% per year.

As of today (2026-07-07), BioCryst Pharmaceuticals's current stock price is $10.99. BioCryst Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-0.60. BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


BioCryst Pharmaceuticals  (NAS:BCRX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BioCryst Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


BioCryst Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for BioCryst Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals Cyclically Adjusted FCF per Share Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.75 -0.79 -0.81 -0.78 -0.61

BioCryst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.80 -0.81 -0.78 -0.61 -0.60

BCRX vs SUPN, PBH, AMLX: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


BCRX
66GF Score
BioCryst Pharmaceuticals Inc BCRX
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCryst Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioCryst Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.257/330.2130*330.2130
=-0.257

Current CPI (Mar. 2026) = 330.2130.

BioCryst Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.177 241.018 -0.243
201609 -0.241 241.428 -0.330
201612 -0.079 241.432 -0.108
201703 -0.113 243.801 -0.153
201706 -0.120 244.955 -0.162
201709 -0.151 246.819 -0.202
201712 -0.108 246.524 -0.145
201803 -0.200 249.554 -0.265
201806 -0.143 251.989 -0.187
201809 -0.333 252.439 -0.436
201812 -0.219 251.233 -0.288
201903 -0.246 254.202 -0.320
201906 -0.223 256.143 -0.287
201909 -0.251 256.759 -0.323
201912 -0.080 256.974 -0.103
202003 -0.152 258.115 -0.194
202006 -0.193 257.797 -0.247
202009 -0.218 260.280 -0.277
202012 -0.242 260.474 -0.307
202103 -0.345 264.877 -0.430
202106 -0.147 271.696 -0.179
202109 -0.132 274.310 -0.159
202112 -0.185 278.802 -0.219
202203 -0.423 287.504 -0.486
202206 -0.151 296.311 -0.168
202209 -0.175 296.808 -0.195
202212 -0.130 296.797 -0.145
202303 -0.253 301.836 -0.277
202306 -0.102 305.109 -0.110
202309 -0.110 307.789 -0.118
202312 -0.047 306.746 -0.051
202403 -0.262 312.332 -0.277
202406 -0.007 314.175 -0.007
202409 0.040 315.301 0.042
202412 -0.028 315.605 -0.029
202503 -0.128 319.799 -0.132
202506 0.187 322.561 0.191
202509 0.183 324.800 0.186
202512 1.328 324.054 1.353
202603 -0.257 330.213 -0.257

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.60 mean?
BioCryst Pharmaceuticals (BCRX) has a Cyclically Adjusted FCF per Share of $-0.60 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioCryst Pharmaceuticals and its competitors.
Is BioCryst Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
BioCryst Pharmaceuticals' current Cyclically Adjusted FCF per Share is $-0.60. Overall, BioCryst Pharmaceuticals has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Cyclically Adjusted FCF per Share compare to SUPN and PBH?
BioCryst Pharmaceuticals' Cyclically Adjusted FCF per Share of $-0.60 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioCryst Pharmaceuticals and its competitors. BioCryst Pharmaceuticals's current Cyclically Adjusted FCF per Share is $-0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.59, compared to a current price of $10.99 — trading 12.7% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $-0.60. BioCryst Pharmaceuticals' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current Cyclically Adjusted FCF per Share is $-0.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of $10.99 is trading 12.7% below its estimated GF Value™ of $12.59. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for BCRX:

  • Cyclically Adjusted FCF per Share: $-0.60
  • GF Value™: $12.59 vs. price of $10.99 (12.7% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:MexicoBO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
66GF Score

Get the complete analysis for BCRX

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.99
Price
$12.59
GF Value